期刊文献+

瑞舒伐他汀强化降脂对高血压病患者颈动脉粥样硬化斑块的影响 被引量:5

The effect of intensive lipid lowering by rosuvastatin on carotid atherosclerotic plaques in patients with hypertension
下载PDF
导出
摘要 目的观察瑞舒伐他汀强化降脂对高血压病患者颈动脉粥样硬化颈动脉内膜-中层厚度(CIMT)及颈动脉斑块的影响。方法 60例高血压合并颈动脉粥样硬化患者随机分为A、B组各30例。试验前测血压、血糖、血脂、肾功能等生化指标,检测CIMT和粥样硬化斑块。A组给予瑞舒伐他汀10mg,每晚1次,贝尼地平4mg,每天1次;B组给予瑞舒伐他汀20mg,每晚1次,贝尼地平4mg,每天1次,控制血压及强化降脂。血压不达标者,加用氢氯噻嗪12.5~25mg,每天1次。治疗6个月后检测CIMT和颈动脉斑块的变化。结果 2组均可降低CIMT和消退颈动脉斑块,差异均有统计学意义(P<0.01)。但B组较A组CIMT降低和颈动脉斑块消退更明显,差异均有统计学意义(P<0.01)。结论高血压病合并颈动脉粥样硬化患者,瑞舒伐他汀强化降脂治疗后可显著降低CIMT,并可以明显消退颈动脉斑块。 Objective To observe the effect of intensive lipid lowering by rosuvastatin on caroid artery intima-media thickness(CIMT)and carotid atherosclerotic plaques in patients with hypertension.Methods 60 cases of hypertension patients with different extent of carotid atheroma were randomly divided into group A and group B,30 cases of each.Blood pressure,blood glucose,serum lipids,renal function,CIMT and carotid atherosclerotic plaques were measured before treatment of the two groups.Group A received benidipine 4mg po qd and rosuvastatin 10mg po qn,Group B received benidipine 4mg po qd and rosuvastatin 20mg po qn.Hydrochlorthiazide 12.5~25mg po qd was added if blood presures not controlled properly.All the patients received the cervical artery ultrasonic,Observed the changes of CIMT and the plaques six months later.Results Both of two groups can efficiently reduced the CIMTs and the plaques The differences were statistically significant(P0.01).In contrast,the CIMTs and the plaques in group B were significantly reduced than that of group A after treatment.The differences were statistically singificant(P0.01).Conclusion Intensive treatment by rosuvastatin can remarkably decrease CIMTs and reduce carotid atherosclerotic plaques significantly.
出处 《临床合理用药杂志》 2010年第11期3-5,共3页 Chinese Journal of Clinical Rational Drug Use
关键词 瑞舒伐他汀 颈动脉粥样硬化斑块 颈动脉内膜-中层厚度 高血压 Rosuvastatin Carotid atherosclerotic plaques Carotid artery intima-media thickness Hypertension
  • 相关文献

参考文献11

二级参考文献100

  • 1史卫国,孙学玉.炎症与高血压[J].临床荟萃,2004,19(21):1255-1256. 被引量:4
  • 2鄢琳,曹立亚,雷建军,兰奋,李静,肖爱丽,邹燕,白雪,章渝,王超,张力文,李幼平.9种调血脂药物有效性及安全性评价[J].中国循证医学杂志,2005,5(1):8-21. 被引量:50
  • 3李晓萌.超声对高血压患者颈动脉粥样硬化的相关性观察[J].中国超声诊断杂志,2006,7(2):127-128. 被引量:32
  • 4黄铮,龚兰生,施仲伟,沈卫峰,于金德.冠心病患者颈动脉粥样硬化斑块的好发部位及其超声分型[J].中国超声医学杂志,1996,12(5):34-37. 被引量:194
  • 5Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广(译),王淑敏(译),胡大一(校).极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志(中文版),2006,25(4):215-223. 被引量:342
  • 6沈稚舟 吴松华 等.糖尿病慢性并发症.糖尿病与肝脏疾病[M].上海:上海医科大学出版社,1999.322.
  • 7Markin A, Lip GY, Silverman S, et al. Peripheral vascular disease and hypertension: a forgotten association [ J ]. J Hum Hypertenss, 2001,15 ( 7 ) :447-454.
  • 8Sasaki R, Yamano S, Yamamoto K, et al. Vascular remodeling of the carotid artery in patients with untreated essential hypertension increases with age [ J ]. Hypertens Res,2002, 25 ( 3 ) : 373-379.
  • 9Lee YH, Cui LH, Shin MH, et al. Associations between carotid intima - media thickness, plaque and cardiovascular risk factors[ J]. J Prey Med Pub Heahh,2006 ,39 :477.
  • 10Parikh A, Daneman D. Is carotid uhr asound a useful tool in assessing cardiovascular disease in individuals with diabete[J]. Diabetes Technor Ther,2004,6:65-69.

共引文献517

同被引文献59

  • 1龚艺,徐劲松,苏海,王卫.他汀类药物对高胆固醇血症患者炎症因子和红细胞膜脂肪酸的影响[J].中国实用内科杂志,2007,27(3):193-195. 被引量:21
  • 2Rosuvastatin Registration Clinical Trial Group.Cardiovascular Institute and Fu Wai Hospital,Peking Union Medical College and Chinese Academy of Medical Science,Beijing 100037,China.瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机双盲多中心对照研究[J].中华心血管病杂志,2007,35(3):207-211. 被引量:117
  • 3PAULS J M, DEAN G S, PETER J. Cost effectiveness of rosuvastatin in treating patients to |ow - density lipoprotein cholesterol gosal compared with atrovastatin, pravastatin, and simvastatin (a US analysis of the STELLAR trial). Am Cardiol J,2005,95 (6) :1314.
  • 4Nissen S E, Tuzcu E M, Schoenhagen P, et o2. Effect of intensive com- pared with moderate lipid - lowering therapy onpragression of coronary a therosclemsis : a randomized controlledtrial . JAMA,2004,291 (9) : 1071.
  • 5Yamada T, azuma A, Sasaki S, et al tin in patients with coronary heartdisease: a sound study . Circ J,2007,71 ( 12 ) : 1845 of atorvasta-.
  • 6Okkels Jensen L, Thayssen P, Pederson K E, et al. Regression of coro- nary atherosclerosis by simvastatin:a serialintravaseular ultrasound stud- y. Circ,2004. 110(3) :265.
  • 7Williams K J, Feig J E, Fisher E A. Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat Clin Pract Car- diovasc Med,2008,5(2) :91.
  • 8Yuan G,A1 -shali K Z, Hegele R A. Hypertriglyceridemia: itsefiology, effects and treatment, hypertriglyeeridemia: its etiology, efects and treat- ment. CMAJ,2007, (176) : 1113.
  • 9Link A, Ayadhi T. Rapid immunomadulation by rosuvastatin in patients- with acute coronary syndrom. Cardiology,2007,3 (6) :32.
  • 10方圻,王钟林,宁田海,邵耕,陈在嘉,陆宗良,李健斋,林传骧,周北凡,诸骏仁,诸永康,陶萍,陶寿淇,龚兰生,顾复生,游凯,戴玉华.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175. 被引量:3067

引证文献5

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部